Search research articles
Contact Us
Filters
Showing results (51-60 of 199) with videos related to
Page
of 20
Sort By:
Cancer
|
June 24, 2010
Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant
Maya Koren-Michowitz, Philipp le Coutre, Justus Duyster, et al.
Transplantation
|
August 7, 2013
CD30-targeted therapy with brentuximab vedotin and DLI in a patient with T-cell posttransplantation lymphoma: induction of clinical remission and cellular immunity
Sebastian Theurich, Kerstin Wennhold, Inga Wedemeyer, et al.
ISRN Hematology
|
April 15, 2014
Pretransplant comorbidities maintain their impact on allogeneic stem cell transplantation outcome 5 years posttransplant: a retrospective study in a single german institution
Jens M Chemnitz, Geothy Chakupurakal, Maya Bäßler, et al.
European Journal of Haematology
|
November 16, 2017
Case Report: A Cryptosporidium infection in a patient with relapsed T-lymphoblastic lymphoma undergoing allogeneic stem cell transplantation
Joanna Schiller, Sebastian Klein, Marianne Engels, et al.
Annals of Hematology
|
October 20, 2021
Allogeneic stem cell transplant recipients admitted to the intensive care unit during the peri-transplant period have unfavorable outcomes-results of a retrospective analysis from a German university hospital
Jorge Garcia Borrega, Jan-Michel Heger, Philipp Koehler, et al.
European Journal of Haematology
|
July 2, 2015
FLAMSA reduced-intensity conditioning is equally effective in AML patients with primary induction failure as well as in first or second complete remission
Udo Holtick, Alexander Shimabukuro-Vornhagen, Geothy Chakupurakal, et al.
European Journal of Haematology
|
November 18, 2014
Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation
Christof Scheid, Donna Reece, Meral Beksac, et al.
JCO Precision Oncology
|
July 10, 2024
Quantitative Integrative Survival Prediction in Multiple Myeloma Patients Treated With Bortezomib-Based Induction, High-Dose Therapy and Autologous Stem Cell Transplantation
Manuela Hummel, Thomas Hielscher, Martina Emde-Rajaratnam, et al.
The Cochrane Database of Systematic Reviews
|
November 26, 2019
Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis
Vanessa Piechotta, Tina Jakob, Peter Langer, et al.
European Journal of Haematology
|
October 8, 2016
Regulatory B10 cells display an altered homoeostasis in acute graft-versus-host disease
Geothy Chakupurakal, María Alejandra Garcia-Marquez, Alexander Shimabukuro-Vornhagen, et al.
Page
of 20
Search research articles
Search
Showing results (51-60 of 199) with videos related to
Sort By:
Page
of 20
Cancer
|
June 24, 2010
Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant
Maya Koren-Michowitz, Philipp le Coutre, Justus Duyster, et al.
Transplantation
|
August 7, 2013
CD30-targeted therapy with brentuximab vedotin and DLI in a patient with T-cell posttransplantation lymphoma: induction of clinical remission and cellular immunity
Sebastian Theurich, Kerstin Wennhold, Inga Wedemeyer, et al.
ISRN Hematology
|
April 15, 2014
Pretransplant comorbidities maintain their impact on allogeneic stem cell transplantation outcome 5 years posttransplant: a retrospective study in a single german institution
Jens M Chemnitz, Geothy Chakupurakal, Maya Bäßler, et al.
European Journal of Haematology
|
November 16, 2017
Case Report: A Cryptosporidium infection in a patient with relapsed T-lymphoblastic lymphoma undergoing allogeneic stem cell transplantation
Joanna Schiller, Sebastian Klein, Marianne Engels, et al.
Annals of Hematology
|
October 20, 2021
Allogeneic stem cell transplant recipients admitted to the intensive care unit during the peri-transplant period have unfavorable outcomes-results of a retrospective analysis from a German university hospital
Jorge Garcia Borrega, Jan-Michel Heger, Philipp Koehler, et al.
European Journal of Haematology
|
July 2, 2015
FLAMSA reduced-intensity conditioning is equally effective in AML patients with primary induction failure as well as in first or second complete remission
Udo Holtick, Alexander Shimabukuro-Vornhagen, Geothy Chakupurakal, et al.
European Journal of Haematology
|
November 18, 2014
Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation
Christof Scheid, Donna Reece, Meral Beksac, et al.
JCO Precision Oncology
|
July 10, 2024
Quantitative Integrative Survival Prediction in Multiple Myeloma Patients Treated With Bortezomib-Based Induction, High-Dose Therapy and Autologous Stem Cell Transplantation
Manuela Hummel, Thomas Hielscher, Martina Emde-Rajaratnam, et al.
The Cochrane Database of Systematic Reviews
|
November 26, 2019
Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis
Vanessa Piechotta, Tina Jakob, Peter Langer, et al.
European Journal of Haematology
|
October 8, 2016
Regulatory B10 cells display an altered homoeostasis in acute graft-versus-host disease
Geothy Chakupurakal, María Alejandra Garcia-Marquez, Alexander Shimabukuro-Vornhagen, et al.
Page
of 20